EUVIMEDEUVIMED entdecken
Crossref

Repaglinide metabolism by human hepatocytes reveals CYP2C8 dominance and misassignment of CYP3A4 by liver subcellular fractions and recombinant enzymes

Tashinga E Bapiro

Drug Metabolism and Disposition · 2026-10 · 54 (10) · 100400

DOI: 10.1016/j.dmd.2026.100400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-10. Verfasst von Tashinga E Bapiro. Beteiligte Einrichtung: DMPK, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom. Electronic address: tashinga.bapiro1@astrazeneca.com. Hauptthemen laut MEDLINE: Hepatocytes, Cytochrome P-450 CYP3A, Cytochrome P-450 CYP2C8, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Repaglinide is an antidiabetic agent and Food and Drug Administration-endorsed clinical CYP2C8 probe with a well characterized human disposition profile in which a dicarboxylic acid, M2, is the main metabolite accounting for 66% of the administered dose. The remainder is distributed among M1 (4%), unchanged repaglinide (2%), M4 (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatocytesCytochrome P-450 CYP3ACytochrome P-450 CYP2C8PiperidinesCarbamatesHypoglycemic AgentsHumansMicrosomes, LiverRecombinant ProteinsLiverSubcellular Fractions

Stichwörter der Autor:innen

Cytochrome P450 phenotypingHuman hepatocytesHuman liver microsomesRepaglinide

Substanzen

repaglinideCytochrome P-450 CYP3ACytochrome P-450 CYP2C8PiperidinesCYP3A4 protein, humanRecombinant ProteinsCarbamatesCYP2C8 protein, humanHypoglycemic Agents

Autor:innen und Institutionen

  • DMPK, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom. Electronic address: tashinga.bapiro1@astrazeneca.com.

Förderung

  • AstraZeneca PLC

Zitieren

APA

Bapiro, T. E. (2026). Repaglinide metabolism by human hepatocytes reveals CYP2C8 dominance and misassignment of CYP3A4 by liver subcellular fractions and recombinant enzymes. Drug Metabolism and Disposition, 54(10), 100400. https://doi.org/10.1016/j.dmd.2026.100400

Vancouver

Bapiro TE. Repaglinide metabolism by human hepatocytes reveals CYP2C8 dominance and misassignment of CYP3A4 by liver subcellular fractions and recombinant enzymes. Drug Metabolism and Disposition. 2026;54(10):100400. doi:10.1016/j.dmd.2026.100400

BibTeX
@article{Bapiro2026,
  author = {Bapiro, Tashinga E},
  title = {Repaglinide metabolism by human hepatocytes reveals CYP2C8 dominance and misassignment of CYP3A4 by liver subcellular fractions and recombinant enzymes},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {10},
  pages = {100400},
  doi = {10.1016/j.dmd.2026.100400}
}
Kostenlos starten →